New drug combo aims to tame immune attack after stem cell transplants
NCT ID NCT07185633
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 23 times
Summary
This study tests a combination of the drug Gecacitinib and steroids as a first treatment for acute graft-versus-host disease (aGVHD), a serious complication after a stem cell transplant. About 25 adults who have already received a transplant and developed moderate to severe aGVHD will take the combination for at least 28 days. The goal is to see how many patients achieve a complete or partial response by day 28.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGVHD are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.